Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.62 |
| ▸ | FLT4 | P35916 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | RARB | P10826 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312827 | 0.87 | KMT2A (0.71) | KMT2AEPHA2FLT4GSK3BRARB | |
| Hydrochloric Acid SCHEMBL10551298 | 0.86 | KMT2A (0.70) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL16101790 | 0.84 | KMT2A (0.78) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5568311 | 0.83 | KMT2A (0.79) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5572182 | 0.83 | KMT2A (0.73) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL14499425 | 0.82 | KMT2A (0.75) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5568328 | 0.82 | KMT2A (0.46) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5571314 | 0.82 | KMT2A (0.71) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL34354 | 0.81 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB | |
| Tosufloxacin SCHEMBL34355 | 0.81 | KMT2A (1.00) | KMT2AEPHA2FLT4GSK3BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KMT2A 3269/4885EPHA2 4821/4885FLT4 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.